Catalogue Number
BD-P0608
Analysis Method
HPLC,NMR,MS
Specification
98.0%(HPLC)
Storage
2-8°C
Molecular Weight
Appearance
Powder
Botanical Source
Ganodermalucidum（Leyss.exFr.）Karst．
Structure Type
Triterpenoids
Category
Standards;Natural Pytochemical;API
SMILES
CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(CC(=O)C3=C2C(CC4C3(CCC(C4(C)C)O)C)O)C)C
Synonyms
Ganoderic acid β/Ganoderic acid A/(7|A,15|A,25r)-7,15-dihydroxy-3,11,23-trioxolanost-8-en-26-oic acid/(3β,7β,25R)-3,7-Dihydroxy-11,15,23-trioxolanost-8-en-26-oic acid/ganoderic acid B/Lanost-8-en-26-oic acid, 3,7-dihydroxy-11,15,23-trioxo-, (3β,7β)-/Ganoderic acid/Lanost-8-en-26-oic acid, 3,7-dihydroxy-11,15,23-trioxo-, (3β,7β,25R)-/(3β,7β)-3,7-Dihydroxy-11,15,23-trioxolanost-8-en-26-oic acid/24,25-Dihydrolanosterol
IUPAC Name
(2R,6R)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid
Density
1.2±0.1 g/cm3
Solubility
Methanol
Flash Point
384.4±28.0 °C
Boiling Point
689.0±55.0 °C at 760 mmHg
Melting Point
InChl
InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21-22,32,34H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,22+,28+,29-,30+/m1/s1
InChl Key
LWPLEHFGBRFRKI-NBCWKOIPSA-N
WGK Germany
RID/ADR
HS Code Reference
2918290000
Personal Projective Equipment
Correct Usage
For Reference Standard and R&D, Not for Human Use Directly.
Meta Tag
provides coniferyl ferulate(CAS#:81907-61-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
No Technical Documents Available For This Product.
25834543
BACKGROUND:
Ganoderic acid B is an important bioactive ingredient isolated from Ganoderma lucidum, and exhibits various pharmacological activities.
AIMS:
To investigate the influence of Ganoderic acid B towards the therapeutic window of trifluoperazine (TFP).
METHODS:
In vitro human liver microsomes (HLMs) incubation system was used to determine the inhibition of Ganoderic acid B towards the glucuronidation of trifluoperazine (TFP).
RESULTS:
Ganoderic acid B exerted concentration-dependent inhibition towards the glucuronidation of TFP. Furthermore, Dixon plot was used to determine the inhibition type. The intersection point was located in the second quadrant in Dixon plot, indicating the competitive inhibition of Ganoderic acid B towards TFP glucuronidation. Through fitting the data using competitive nonlinear fitting equation, the inhibition kinetic parameter was calculated to be 56.7 uM.
CONCLUSION:
All this data indicated the potential influence of Ganoderic acid B-containing herbs towards therapeutic window of TFP. Given that the glucuronidation reaction of TFP is the probe reaction of UGT1A4, the data obtained from the present study also indicated the potential influence of Ganoderic acid-containing herbs towards the therapeutic window of drugs mainly undergoing UGT1A4-mediated metabolism.
Ganoderic acid B; UDP-glucuronosyltransferase (UGT) 1A4; trifluoperazine (TFP)
Ganoderic acid B's influence towards the therapeutic window of trifluoperazine (TFP).
Guo J1, Ni C2, Liu X3, Liu T4.
2015 Mar
12575063
The paper reports the assay of ganoderic acid B from Ganoderma lucidum in different places and stages by means of HPLC. The results show that contents of ganoderic acid B from different cultured places have differnces, different stages have effect on the amount too.
[Effects of places and stages on the contents of ganoderic acid B from Ganoderma lucidum].
Ding P1, Zhen Y, Lai X, Xu H.
1999 Jun
